Molecularly Targeted Therapy for Advanced Hepatocellular Carcinoma in 2012: Current Status and Future Perspectives

被引：100

作者：

Zhu, Andrew X. ^{[1
]}

机构：

[1] Harvard Univ, Ctr Canc, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA

来源：

SEMINARS IN ONCOLOGY | 2012年 / 39卷 / 04期

关键词：

ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; RECEPTOR TYROSINE KINASES; PROGNOSTIC-SIGNIFICANCE; FACTOR-ALPHA; OPEN-LABEL; ANTITUMOR-ACTIVITY; TUMOR PROGRESSION; EXPRESSION; BEVACIZUMAB;

D O I：

10.1053/j.seminoncol.2012.05.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：493 / 502

页数：10

共 65 条

[51]

Phase II Trial of the Combination of Bevacizumab and Erlotinib in Patients Who Have Advanced Hepatocellular Carcinoma [J].

Thomas, Melanie B. ;

Morris, Jeffrey S. ;

Chadha, Romil ;

Iwasaki, Michiko ;

Kaur, Harmeet ;

Lin, Elinor ;

Kaseb, Ahmed ;

Glover, Katrina ;

Davila, Marta ;

Abbruzzese, James .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) :843-850

[52]

Toh H, 2009, J CLIN ONCOL, V27

[53]

Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma [J].

Villanueva, Augusto ;

Chiang, Derek Y. ;

Newell, Pippa ;

Peix, Judit ;

Thung, Swan ;

Alsinet, Clara ;

Tovar, Victoria ;

Roayaie, Sasan ;

Minguez, Beatriz ;

Sole, Manel ;

Battiston, Carlo ;

van Laarhoven, Stijn ;

Fiel, Maria I. ;

Di Feo, Analisa ;

Hoshida, Yujin ;

Yea, Steven ;

Toffanin, Sara ;

Ramos, Alex ;

Martignetti, John A. ;

Mazzaferro, Vincenzo ;

Bruix, Jordi ;

Waxman, Samuel ;

Schwartz, Myron ;

Meyerson, Matthew ;

Friedman, Scott L. ;

Llovet, Josep M. .

GASTROENTEROLOGY, 2008, 135 (06) :1972-1983

[54]

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis [J].

Wilhelm, SM ;

Carter, C ;

Tang, LY ;

Wilkie, D ;

McNabola, A ;

Rong, H ;

Chen, C ;

Zhang, XM ;

Vincent, P ;

McHugh, M ;

Cao, YC ;

Shujath, J ;

Gawlak, S ;

Eveleigh, D ;

Rowley, B ;

Liu, L ;

Adnane, L ;

Lynch, M ;

Auclair, D ;

Taylor, I ;

Gedrich, R ;

Voznesensky, A ;

Riedl, B ;

Post, LE ;

Bollag, G ;

Trail, PA .

CANCER RESEARCH, 2004, 64 (19) :7099-7109

[55]

Yamaguchi R, 2000, ONCOL REP, V7, P725

[56]

Expression of vascular endothelial growth factor in human hepatocellular carcinoma [J].

Yamaguchi, R ;

Yano, H ;

Iemura, A ;

Ogasawara, S ;

Haramaki, M ;

Kojiro, M .

HEPATOLOGY, 1998, 28 (01) :68-77

[57]

Yau T, 2012, INVEST NEW DRUGS

[58]

Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics [J].

Yau, Thomas ;

Chen, Pei-Jer ;

Chan, Pierre ;

Curtis, C. Martin ;

Murphy, Philip S. ;

Suttle, A. Benjamin ;

Gauvin, Jennifer ;

Hodge, Jeffrey P. ;

Dar, Mohammed M. ;

Poon, Ronnie T. .

CLINICAL CANCER RESEARCH, 2011, 17 (21) :6914-6923

[59]

YEH YC, 1987, CANCER RES, V47, P896

[60]

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma [J].

Zhu, Andrew X. ;

Stuart, Keith ;

Blaszkowsky, Lawrence S. ;

Muzikansky, Alona ;

Reitberg, Donald P. ;

Clark, Jeffrey W. ;

Enzinger, Peter C. ;

Bhargava, Pankaj ;

Meyerhardt, Jeffrey A. ;

Horgan, Kerry ;

Fuchs, Charles S. ;

Ryan, David P. .

CANCER, 2007, 110 (03) :581-589

← 1 2 3 4 5 6 7 →